These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12784381)

  • 1. Results from controlled clinical trials: how relevant for clinical practice?
    Kvien TK; Mikkelsen K; Nordvåg BY
    J Rheumatol; 2003 Jun; 30(6):1135-7. PubMed ID: 12784381
    [No Abstract]   [Full Text] [Related]  

  • 2. A modest proposal.
    Lipsky PE
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):343. PubMed ID: 16932714
    [No Abstract]   [Full Text] [Related]  

  • 3. Current management of rheumatoid arthritis.
    Tambar S; Ruderman EM
    Manag Care Interface; 2007 Jul; 20(7):18-24. PubMed ID: 17849729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus.
    Yazici Y; Erkan D
    Arthritis Rheum; 2003 Dec; 48(12):3611; author reply 3613-5. PubMed ID: 14674017
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescribing trends for targeted therapies in rheumatoid arthritis among rheumatologists in Southern California, 2008-2010.
    Bagheri S; Wallace DJ
    Arthritis Rheum; 2011 Nov; 63(11):3641. PubMed ID: 21769837
    [No Abstract]   [Full Text] [Related]  

  • 6. Observational cohort studies and well controlled clinical trials--we need them both!
    Furst DE
    J Rheumatol; 2004 Aug; 31(8):1476-7. PubMed ID: 15290723
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gold preparations in therapy of rheumatoid and psoriatic arthritis].
    Nasonova VA; Lukina GV; Sigidin IaA; Badokin VV
    Ter Arkh; 2003; 75(5):88-90. PubMed ID: 12847908
    [No Abstract]   [Full Text] [Related]  

  • 8. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 9. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness.
    Wolfe F; Michaud K
    Rheumatology (Oxford); 2005 Dec; 44 Suppl 4():iv18-iv22. PubMed ID: 16306476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating to target in rheumatoid arthritis - challenges and opportunities.
    Ruderman EM
    Bull Hosp Jt Dis (2013); 2013; 71(3):214-7. PubMed ID: 24151948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
    Hetland ML; Lindegaard HM; Hansen A; Pødenphant J; Unkerskov J; Ringsdal VS; Østergaard M; Tarp U
    Ann Rheum Dis; 2008 Jul; 67(7):1023-6. PubMed ID: 18272669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counterpoint from the trenches: a pragmatic approach to therapeutic trials in rheumatoid arthritis.
    Strand V
    Arthritis Rheum; 2004 Apr; 50(4):1344-7. PubMed ID: 15077319
    [No Abstract]   [Full Text] [Related]  

  • 14. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of rheumatoid arthritis in standard clinical care: turning clinical care into clinical science.
    Sokka T
    Best Pract Res Clin Rheumatol; 2007 Aug; 21(4):653-61. PubMed ID: 17678827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for monitoring of methotrexate therapy: "evidence-based medicine" outside of clinical trials.
    Pincus T
    Arthritis Rheum; 2003 Oct; 48(10):2706-9. PubMed ID: 14558072
    [No Abstract]   [Full Text] [Related]  

  • 17. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Charting the possible impact of national guidelines on the management of rheumatoid arthritis.
    Carli C; Bridges JF; Ask J; Lindblad S;
    Scand J Rheumatol; 2008; 37(3):188-93. PubMed ID: 18465453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All patients with rheumatoid arthritis should receive corticosteroids as part of their management.
    Carette S
    J Rheumatol; 2007 Apr; 34(4):656-60. PubMed ID: 17407224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.